Institution
Victor Chang Cardiac Research Institute
Nonprofit•Sydney, New South Wales, Australia•
About: Victor Chang Cardiac Research Institute is a nonprofit organization based out in Sydney, New South Wales, Australia. It is known for research contribution in the topics: Mechanosensitive channels & Heart failure. The organization has 708 authors who have published 1599 publications receiving 70035 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This study describes the first electrophysiological characterization of an MscS-like channel from a marine bacterium belonging to sulfur-degrading α-proteobacteria and investigates its response to membrane tension using the patch-clamp technique.
28 citations
••
TL;DR: Detailed protocols used for the preparation of giant spheroplasts as well as protocols for the patch-clamp recording of native or heterologously expressed ion channels in E. coli sp Heroplast membrane are described.
Abstract: Ion channel studies have been focused on ion channels from animal and human cells over many years. Based on the knowledge acquired, predominantly over the last 20 years, a large diversity of ion channels exists in cellular membranes of prokaryotes as well. Paradoxically, most of what is known about the structure of eukaryotic ion channels is based on the structure of bacterial channels. This is largely due to the suitability of bacterial cells for functional and structural studies of biological macromolecules in a laboratory environment. Development of the "giant spheroplast" preparation from E. coli cells was instrumental for functional studies of ion channels in the bacterial cell membrane. Here we describe detailed protocols used for the preparation of giant spheroplasts as well as protocols used for the patch-clamp recording of native or heterologously expressed ion channels in E. coli spheroplast membrane.
28 citations
••
TL;DR: It is shown that saturation mutagenesis of Phe(303) results in a series of mutants with different levels of constitutive activity for inositol phosphate (IP) signaling, and that the F303A and F303L mutants result in TM helical movements that differ in accordance with their degree of constitutively active activity.
Abstract: We showed previously that Phe(303) in transmembrane segment (TM) VI of the alpha(1B)-adrenergic receptor, a highly conserved residue in G-protein-coupled receptors (GPCRs), is critically involved in receptor-activation and G-protein-coupling [Chen, S. H., Lin, F., Xu, M., Hwa, J., and Graham, R. M. (2000) EMBO J. 19, 4265-4271]. Here, we show that saturation mutagenesis of Phe(303) results in a series of mutants with different levels of constitutive activity for inositol phosphate (IP) signaling. Mutants F303G and F303N showed neither basal nor agonist-stimulated IP turnover, whereas F303A displayed increased basal activity but an attenuated maximal response to (-)-epinephrine-stimulation. F303L, on the other hand, showed all features of a typical constitutively active GPCR with markedly increased basal activity and increased potency and efficacy of agonist-stimulated IP signaling. All mutants displayed higher agonist-binding affinities than the wild-type receptor, and by thermal stability studies, those able to signal showed increased susceptibility to inactivation with an order of sensitivity (F303L > F303A > WT) directly related to their degree of constitutive activity. Using the substituted cysteine accessibility method (SCAM) and equilibrium binding studies, we further show that the F303A and F303L mutants result in TM helical movements that differ in accordance with their degree of constitutive activity. These findings, therefore, confirm and extend our previous data implicating Phe(303) as a key residue coupling TM helical movements to G-protein-activation.
28 citations
••
TL;DR: Serum exosomal-miRNA signatures can accurately diagnose glioblastoma preoperatively and appear to be superior to previously reported ‘free-circulating’ miRNA studies in GBM patients.
Abstract: Exosomes are nano-sized extracellular vesicles released by many cells that contain molecules characteristic of their cell-of-origin, including microRNA. Exosomes released by glioblastoma cross the blood-brain-barrier into the peripheral circulation, and carry molecular cargo distinct to that of free-circulating miRNA. In this pilot study, serum exosomal-microRNAs were isolated from glioblastoma (n=12) patients and analyzed using unbiased deep sequencing. Results were compared to sera from age- and gender-matched healthy controls, and to grades II-III (n=10) glioma patients. Significant differentially expressed microRNAs were identified, and the predictive power of individual and subsets of microRNAs were tested using univariate and multivariate analyses. Additional sera from glioblastoma patients (n=4) and independent sets of healthy (n=9) and non-glioma (n=10) controls were used to further test the specificity and predictive power of this unique exosomal-microRNA signature. Twenty-six microRNAs were differentially expressed in serum exosomes from glioblastoma patients relative to healthy controls. Random forest modeling and data partitioning selected seven miRNAs (miR-182-5p, miR-328-3p, miR-339-5p, miR-340-5p, miR-485-3p, miR-486-5p and miR-543) as the most stable for classifying glioblastoma. Strikingly, within this model, six iterations of these miRNA classifiers could distinguish glioblastoma patients from controls with perfect accuracy. The seven-miRNA panel was able to correctly classify all specimens in validation cohorts (n=23). Also identified were 23 dysregulated miRNAs in IDHMUT gliomas, a partially overlapping yet distinct signature of lower grade glioma. Serum exosomal-miRNA signatures can accurately diagnose glioblastoma preoperatively. miRNA signatures identified are distinct from previously reported free-circulating miRNA studies in GBM patients, and appear to be superior.
28 citations
••
TL;DR: In this paper, the authors identify a structurally defined pathway for vaccine strategies eliciting escape-resistant SARS-CoV-2 neutralizing antibodies using a human antibody repertoire with diverse RBDs to identify antibodies targeting conserved sites of vulnerability.
28 citations
Authors
Showing all 728 results
Name | H-index | Papers | Citations |
---|---|---|---|
Bruce D. Walker | 155 | 779 | 86020 |
Stefanie Dimmeler | 147 | 574 | 81658 |
Matthias W. Hentze | 110 | 319 | 41879 |
Roland Stocker | 92 | 331 | 34364 |
Richard P. Harvey | 83 | 403 | 27060 |
Michael F. O'Rourke | 81 | 451 | 35355 |
Robert Terkeltaub | 80 | 284 | 21034 |
Robert M. Graham | 69 | 319 | 16342 |
Sunil Gupta | 69 | 440 | 33856 |
Anne Keogh | 64 | 337 | 20268 |
Filip K. Knop | 61 | 437 | 13614 |
Peter S. Macdonald | 57 | 455 | 12988 |
Boris Martinac | 56 | 245 | 14121 |
Carolyn L. Geczy | 55 | 187 | 8987 |
Christopher J. Ormandy | 54 | 131 | 8757 |